MedTrace Logo

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

NCT03506568 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-02-21

Study results available
· View outcomes & findings →

Summary

Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective. However, adherence to eye drop treatment is poor with only 50% of patients regularly taking their prescribed eye drops. The investigators are developing the Devers Drop Device (D3) eye drop monitor to accurately measure eye drop cap removal and to improve eye drop-taking behavior. The investigators will test eye drop adherence with the D3 device in a randomized, prospective clinical trial.

Conditions

Interventions

DEVICE

Devers Drop Device (D3) app

A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Oregon State University

    collaborator OTHER

  • National Eye Institute (NEI)

    collaborator NIH

  • Universal Adherence LLC

    lead INDUSTRY

Principal Investigators

  • Steve L Mansberger, MD · Universal Adherence LLC

  • David Porter, PhD · Oregon State University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-02
Primary Completion
2021-06-04
Completion
2021-06-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506568 on ClinicalTrials.gov